uncategorized

November 12, 2020November 12, 2020

Inovelon/Banzel Seen to Treat LGS Seizures Without Hindering Cognition

uncategorized

The add-on anti-seizure therapy Inovelon (rufinamide) shows good tolerability, with one year of treatment not affecting cognitive abilities, adaptive skills, or behavior in children and adults with Lennox-Gastaut syndrome (LGS), ... Read more

October 15, 2020October 15, 2020

Australian TGA Approves Epidyolex for Treating Seizures Associated with LGS

uncategorized

The Australian Therapeutic Goods Administration (TGA) has approved Epidyolex (cannabidiol) as a treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients 2 or older, according to developers ... Read more

October 8, 2020October 8, 2020

Eton Pharmaceuticals Submits New Drug Application for Topiramate Oral Solution

uncategorized

Eton Pharmaceuticals has submitted a new drug application (NDA) for topiramate oral solution — an anticonvulsant formerly known as ET-101 — to the U.S. Food and Drug Administration (FDA). The NDA covers three indications: ... Read more

October 1, 2020October 1, 2020

Epidyolex Approved in Scotland to Treat LGS Patients, 2 and Older

uncategorized

The Scottish Medicines Council (SMC) approved Epidyolex (cannabidiol), combined with the anti-epileptic medicine clobazam, as a treatment option for children and adults with Lennox-Gastaut or Dravet Syndrome. Eligible patients, ages ... Read more

September 24, 2020September 24, 2020

EU Panel Favors Fycompa’s Age Range to Include Children Younger Than 12

uncategorized

A European Medicines Agency (EMA) committee has recommended that the age range of Fycompa (perampanel) be expanded in the European Union (EU) to include children 4 and older with focal-onset seizures and those 7 ... Read more

September 17, 2020September 17, 2020

Epidiolex-Valproic Acid Combo Can Lower Platelet Counts in Children With LGS, Study Finds

uncategorized

When used alongside valproic acid, Epidiolex (cannabidiol) can increase the risk of thrombocytopenia in children and adolescents with drug-resistant forms of epilepsy, such as Lennox-Gastaut syndrome (LGS), a study shows. According ... Read more

September 10, 2020September 10, 2020

Soticlestat Safely Lowered Seizure Frequency in Children With LGS, Top-line Data Show

uncategorized

Treatment with soticlestat (OV935/TAK-935) safely led to a clinically meaningful reduction in the frequency of hard-to-treat seizures in a group of children with Dravet and Lennox-Gastaut (LGS) syndromes, according to top-line ... Read more

August 20, 2020August 20, 2020

FDA Expands Age Range for Epidiolex for Treating LGS Seizures

uncategorized

The U.S. Food and Drug Administration (FDA) has expanded the age range of patients to whom Epidiolex (cannabidiol) can be prescribed, to include children as young as age 1, according to ... Read more

August 18, 2020August 18, 2020

Epilepsy Foundation’s Community Day is Virtual This Year

uncategorized

The Epilepsy Foundation’s Community Day, being held virtually this year, will offer patients, caregivers, and advocates the latest information about epilepsy and an opportunity to connect with others. “Innovation and Action ... Read more

August 6, 2020August 6, 2020

Epidiolex Helps Control Seizures in Children Without Affecting Cognition, Study Reports

uncategorized

Epidiolex, a cannabidiol add-on medication for treatment-resistant epilepsy, was safely given to children and teenagers for one year in a clinical trial that included youth with Lennox-Gastaut syndrome, a study reported. ... Read more